Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
Ling Lin1 ,* Xiaomai Wu1 ,* Shuangquan Yan,1 Yefei Zhu,1 Zhengqing Yan,2 Dongqing Lv,1 Hongfei Ge3 1Department of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, People’s Republic of China; 2The Medical Department, 3D Medicines Inc., Shanghai, People&rsqu...
Main Authors: | Lin L, Wu X, Yan S, Zhu Y, Yan Z, Lv D, Ge H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/response-to-afatinib-in-a-patient-with-nsclc-harboring-novel-egfr-exon-peer-reviewed-article-OTT |
Similar Items
-
Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
by: Sabine Zöchbauer-Müller, et al.
Published: (2021-01-01) -
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021-07-01) -
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
by: Bo Yuan, et al.
Published: (2020-05-01) -
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
by: Nahomi Tokudome, et al.
Published: (2020-02-01) -
Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
by: Lingling Zhao, et al.
Published: (2021-04-01)